Our products and services are essential components for the research, development and production of new generation medicines as for example vaccines, immuno-oncology therapies, and protein replacement treatments.
Discover our latest initiatives, technology advancements, expansion plans, and our ongoing commitment to research and development of cutting-edge solutions for Cell & Gene Therapies and Nucleic Acids.
We are excited to announce that Advanced Therapies USA 2025 (November 18-19, Philadelphia) will bring together the entire ecosystem of advanced therapies – and we at Anemocyte are proud to be part of it.
read moreAnemocyte Srl is set to make a significant contribution to the 13th International mRNA Health Conference in Berlin and online, from November 11 to 13, 2025.
read moreAnemocyte will participate in TIDES Europe 2025, taking place in Basel, Switzerland, from 11 to 13 November 2025.
read moreGenenta Science and ANEMOCYTE, today announced a strategic collaboration with a focus on off-the-shelf lentiviral vector (“LVV”) Plasmid DNA technology platform.
read moreAnemocyte is pleased to announce its participation in CPHI Europe 2025, taking place in Frankfurt, Germany, from October 28 to 30, 2025, at Messe Frankfurt.
read moreWe are delighted to announce Anemocyte’s participation in BioJapan / Regenerative Medicine Japan / healthTECH Japan 2025, taking place from October 8–10, 2025 at PACIFICO Yokohama.
read moreWe are proud to announce Anemocyte’s participation in the Cell & Gene Meeting on the Mesa, taking place in Phoenix, Arizona, from October 6 to 8, 2025.
read moreWe’re proud to announce that we’ll be attending the 2nd Annual Meeting of the Society for mRNA Medicines, in Coronado (CA) from September 16–18, 2025.
read moreWe’re thrilled to announce that our team will participate in RNA Leaders USA 2025, taking place in Boston on September 10-11
read moreWe are excited to announce that our team will be attending Advanced Therapies Europe 2025 in Barcelona, 2-4 September 2025.
read moreFrom July 21st to 23rd, 2025, Boston will host one of the most influential gatherings in the field of mRNA innovation: the mRNA-Based Therapeutics Summit USA.
read moreWe’re among the Alliance for Regenerative Medicine (ARM) leaders calling on the EU to act for the future of advanced therapies in Europe.
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
